Comparison of acellular pertussis-based combination vaccines by Japanese control tests for toxicities and laboratory models for local reaction

Vaccine

Volumn 27, Issue 13, 2009, Pages 1881-1888

  Kataoka, Michiyo ^a   Yamamoto, Akihiko ^a   Ochiai, Masaki ^a   Harashima, Ayako ^a   Nagata, Noriyo ^a   Hasegawa, Hideki ^a   Kurata, Takeshi ^a   Horiuchi, Yoshinobu ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

Acellular pertussis vaccine; Local reaction; Quality control

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HISTAMINE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODYWEIGHT DECREASING TOXICITY TEST; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG QUALITY; DRUG SAFETY; EXPERIMENTAL MODEL; FEMALE; HISTAMINE SENSITIZING TOXICITY TEST; INFLAMMATION; INJECTION SITE REACTION; JAPANESE; LEUKOCYTOSIS PROMOTING TOXICITY TEST; MOUSE; MOUSE FOOTPAD SWELLING MODEL; MOUSE INTRAMUSCULAR INJECTION MODEL; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RABBIT; RABBIT SKIN SWELLING MODEL; TISSUE INJURY; TOXICITY TESTING; VACCINE PRODUCTION;

ANIMALS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; EDEMA; FEMALE; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; POLIOVIRUS VACCINE, INACTIVATED; RABBITS; TOXICITY TESTS;

EID: 61349126453     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.095     Document Type: Article

References (29)

1. Kanai K. Japan's experience in pertussis epidemiology and vaccination in the past thirty years. Jpn J Med Sci Biol 33 (1980) 107-143
2. Kurokawa M. Toxicity and toxicity testing of pertussis vaccine. Jpn J Med Sci Biol 37 (1984) 41-81
3. Ministry of Health and Welfare, Japanese Government, Minimum Requirements for Biological Products of Japan; 2006.
4. Kimura M., and Kuno-Sakai H. Experiences with acellular pertussis vaccine in Japan and epidemiology of pertussis. Tokai J Exp Clin Med 12 (1987) 263-273
5. Torvaldsen S., Hull B.P., and McIntyre P.B. Using the Australian Childhood Immunisation Register to track the transition from whole-cell to acellular pertussis vaccines. Commun Dis Intell 26 4 (2002) 581-583
6. Le Saux N., Barrowman N.J., Moore D.L., Whiting S., Scheifele D., and Halperin S. Canadian Paediatric Society/Health Canada Immunization Monitoring Program-Active (IMPACT). Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 112 5 (2003) e348
7. Rennels M.B., Deloria M.A., Pichichero M.E., Losonsky G.A., Englund J.A., Meade B.D., et al. Extensive swelling after booster doses of acellular pertussis. Tetanus Diphtheria Vaccines Pediatrics 105 (2000) 1-6
8. Skowronski D.M., Remple V.P., Macnabb J., Pielak K., Patrick D.M., Halperin S.A., et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 112 (2003) e453-e459
9. Gold M.S., Noonan S., Osbourn M., Precepa S., and Kempe A.E. Local reactions after the fourth-dose of acellular pertussis vaccine in South Australia. Med J Aust 179 (2003) 191-194
10. Rennels M.B. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 14 3 (2003) 196-198 [Review]
11. Manclark C.R., Urban M.A., Summers E.P., and Vickers J.H. Assay of pertussis vaccine toxicity by a rat-paw-oedema method. J Med Microbiol 10 1 (1977) 115-120
12. Pruchova J., Vrana M., and Sladky K. Studies of local reactivity to B. pertussis suspensions by means of the rat paw oedema. J Hyg Epidemiol Microbiol Immunol 22 1 (1978) 47-52
13. Munoz J.J., Robbins K.E., and Cole R.L. Reactions in the foot pads of mice induced by pertussigen and endotoxin from Bordetella pertussis. J Reticuloendothel Soc 27 3 (1980) 259-268
14. Ishida S., Iwasa S., Akama K., Asakawa S., Tai M., and Kurokawa M. The quantitative determination of the paw-swelling activity of pertussis vaccine with special reference to its responsible toxic components. Jpn J Med Sci Biol 36 3 (1983) 157-170
15. Sakuma S., Imagawa Y., Tokunaga E., and Ohtomo N. Increase in intradermal vascular permeability caused by pertussis toxin from Bordetella pertussis. Microbiol Immunol 31 6 (1987) 531-539
16. Pineau A., Durand C., Guillard O., Bureau B., and Stalder J.F. Role of aluminium in skin reactions after diphtheria-tetanus-pertussis-poliomyelitis vaccination: an experimental study in rabbits. Toxicology 73 1 (1992) 117-125
17. Ishida S. Characterization of the body weight-decreasing toxicities in mice by the lymphocytosis-promoting factor and the heat-labile toxin or B. pertussis and endotoxin. Jpn J Med Sci Biol 21 (1968) 115-135
18. Iwasa S., Ishida S., Asakawa S., and Kurokawa M. Lymphocytosis-promoting factor produced by Bordetella pertussis. Jpn J Med Sci Biol 21 (1963) 363-368
19. Ishida S., Kurokawa M., Asakawa S., and Iwasa S. A sensitive assay method for the histamine-sensitizing factor using change in rectal temperature of mice after histamine challenge as a response. J Biol Stand 7 (1979) 21-29
20. Finney D.J. Statistical methods in biological assay. 3rd ed. (1978), Charles Griffin, London
21. Iwasa S., Ishida S., Asakawa S., and Akama K. A curious histamine-sensitizing activity shown by the newly-developed Japanese acellular pertussis vaccine. Dev Biol Stand 61 (1985) 453-460
22. Horiuchi Y., Feng D.J., Kameyama S., Takahashi M., Asada S., Asakawa S., et al. Two different histamine-sensitizing activities of pertussis vaccine observed in mice on the 4th and 12th days of sensitization. Jpn J Med Sci Biol 46 (1993) 17-27
23. Obayashi T., Tamura H., Tanaka S., Ohki M., Takahashi S., Arai M., et al. A new chromogenic endotoxin-specific assay using recombined Limulus coagulation enzymes and its clinical applications. Clin Chim Acta 149 (1985) 55-65
24. Tanaka S., and Iwanaga S. Limulus test for detecting bacterial endotoxins. Methods Enzymol 223 (1993) 358-364
25. Horiuchi Y., Takahashi M., Asada S., and Ishida S. Increased levels of active pertussis toxin may aid a pertussis vaccine to pass the mouse body weight gain test. Biologicals 22 (1994) 243-248
26. Ryan M., McCarthy L., Rappuoli1 R., Mahon B.P., and Mills K.H.G. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int Immunol 10 5 (1998) 651-662
27. Loosmore S., Zealey G., Cockle S., Boux H., Chong P., Yacoob R., et al. Characterization of pertussis toxin analogs containing mutations in b-oligomer subunits. Infect Immun 61 6 (1993) 2316-2324
28. Elisabet B., Birger T., and Annica I. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 22 (2003) 64-69
29. Bergfors E., Björkelund C., and Trollfors B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium-adsorbed vaccines. Eur J Pediatr 164 (2005) 691-697